Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 10/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21837386 | 0.90 | KYNU (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL21837385 | 0.90 | KYNU (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL28162782 | 0.89 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL1832552 | 0.89 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL1837491 | 0.89 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL5191992 | 0.89 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL16351361 | 0.88 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL31604948 | 0.88 | KYNU (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL527104 | 0.87 | CTSK (0.64) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL4387860 | 0.87 | CTSK (0.64) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | KYNU 1784/4885ALDH1A1 139/4885ALOX15 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.